Teriparatide at a glance;Teriparatid - Ein überblick

Arzneimitteltherapie

Volumn 28, Issue 9, 2010, Pages 277-282

  Lehmann, Gabriele ^a   Wolf, Gunter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Bone remodelling; Fracture risk reduction; Teriparatide

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; CALCIUM; COLECALCIFEROL; GLUCOCORTICOID; PARATHYROID HORMONE[1-34];

BONE DENSITY; BONE MASS; BONE MINERAL; BONE REMODELING; BONE STRUCTURE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIZZINESS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG INDICATION; FEMALE; FRACTURE; HEADACHE; HEART PALPITATION; HUMAN; HYPOGONADISM; IDIOPATHIC DISEASE; MALE; MICRO-COMPUTED TOMOGRAPHY; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK REDUCTION; TREATMENT OUTCOME;

EID: 77956657443     PISSN: 07236913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Papapoulos SE, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005;16:468-74.
2. Thiebaud D, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103:298-307. (Pubitemid 27459256)
3. Reginster J, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 2000;11:83-91.
4. Levis S, et al. Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 2002;50:409-15.
5. Brown JP, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-11.
6. Black DM, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
7. Brown EM. Physiology and pathophysiology of the extracellular calcium-sensing receptor. Am J Med 1999;106:238-53.
8. Morley P, et al. Parathyroid hormone: an anabolic treatment for osteoporosis. Curr Pharm Des 2001;7:671-87. (Pubitemid 32427768)
9. rd edition. Lippincott Raven, 1996:68-70.
10. Fu Q, et al. Parathyroid hormone stimulates receptor activator of NF kappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 2002;277:48868-75.
11. Lee SK, Lorenzo JA. Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. Bone 2002;31:252-9.
12. Ma YL, et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001;142:4047-54.
13. Jiang Y, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-41.
14. Dempster DW, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53.
15. Compston JE. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 2007;40:1447-52.
16. Bauer W, et al. Studies of calcium and phosphorus metabolism. V. A study of the bone trabecular as a readily available reserve of calcium. J Exp Med 1929;49:145-61.
17. Niall HD, et al. The amino-acid sequence of the amino-terminal 37 residues of human parathyroid hormone. Proc Natl Acad Sci U S A 1974;71:384-8.
18. Reeve J, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1980;280:1340-4. (Pubitemid 10124272)
19. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997;138:4607-12.
20. Jilka RL, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439-46.
21. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995;136:3632-8.
22. Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption - a hypothesis. Calcif Tissue Int 1981;33:349-51.
23. Blick SK, et al. Teriparatide: a review of its use in osteoporosis. Drugs 2008;68:2709-37.
24. Miller PD, et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 2007;18:59-68.
25. Neer RM, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
26. Genant HK, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Min Res 1993;8:1137-48.
27. Neuprez A, Reginster JY. Bone-forming agents in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008;22:869-83.
28. Orwoll ES, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17. (Pubitemid 36008334)
29. Ettinger B, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-51. (Pubitemid 41094385)
30. Boonen S, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008;93:852-60. (Pubitemid 351398563)
31. Stepan JJ, et al. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int 2010 Feb 5. [Epub ahead of print].
32. Saag KG, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39.
33. Langdahl BL, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009;20:2095-104.
34. Lindsay R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164:2024-30. (Pubitemid 39390560)
35. Cosman F, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001;16:925-31. (Pubitemid 32332303)
36. Rittmaster RS, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-34.
37. Fachinformation Forsteo®, Stand Marz 2010.
38. Tashjian AH Jr., Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002;17:1151-61.
39. Vahle JL, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312-21.
40. DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Osteologie 2009;18:304-28.
41. McClung MR, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8.
42. Satterwhite J, et al. Men and postmenopausal women with osteoporosis have similar lumbar spine bone mineral density responses to recombinant human parathyroid hormone (1-34) despite pharmacokinetic and biochemical marker differences. Arthritis Rheum 2001;44(Suppl 9):255.
43. Obermayer-Pietsch B, et al. Response of BMD to 24 months of teriparatide (rhPTH 1-34) in patients with and without prior antiresorptive treatment: final results from the EUROFORS Study. J Bone Miner Res 2006;21(Suppl.1):43.